CD8A and cancer: Recent studies and clinical trials on cancer immunotherapies (e.g., ICIs and CAR-T cells) aimed at improving the antitumor function of CD8+ T cells have shown several encouraging successes with promising outcomes and significantly ameliorated the prognosis of cancer patients [11, 12].